Home

WESEEYOU

Intercept’s commitment to research is a commitment to you

The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

LEARN ABOUT PBC AND NASH >

News

Tuesday, May 19, 2015

Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH
See the press release >